The dynamics of pharmaceutical buyouts and drug development

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of Mounjaro. But with competitors desperate for a piece of the action, how long can these two giants stay in front?

Leanna Byrne hears from some of the companies involved, including those at the centre of the action and those developing the next wave of treatments.

Presented by Leanna Byrne and produced by Lexy O'Connor

(Image: A box of the anti-obesity drug Wegovy, including injection pens. Credit: Getty Images)